Nesina,Nesina, drug, newerdrug, newdrug, FDA, Pharmacy, pharmd, vels, therapeutics, algoliptin

1. DRUG FOR THE WEEK
NESINA

2. NESINA
•Therapeutic class:-Dipeptidyl peptidase 4-inhibitor
•Generic name:-Alogliptin benzoate
•Trade name:-Nesina
•FDA Approved date :- 26 January 2013

3. •Company name:- Takeda
•Cost:- 25 mg (Rs.209.40) ,12.5 mg(Rs.112.20), 6.25mg
(Rs.60.40)
•
•Indications:- Type 2 diabetes mellitus
•Dosage:-
• Adults:- Usual- 25mg- qd
• Renal Impairment: Moderate : 12.5mg qd
•. End-Stage Renal Disease/severe: 6.25mg qd.
•Pregnancy:-
•Category B

4. •Mechanism of action:-
It increases the activation of incretin hormones, thereby
increasing their bloodstream concentrations and reducing fasting
postprandial glucose concentrations .
•Pharmacokinetics:-
Absorption:- Absolute bioavailability (100%)
Distribution:- 20% plasma protein binding
Metabolism:- hepatic metabolism occurs
Elimination:- Feces (13%), Urine (76%), T1/2=21 hrs

5. •Adverse drug reactions:-
• Hypoglycemia
• Nasopharyngitis
•Throbbing headache
•Drug interactions:-
• Bexarotene
• Gatifloxacin

6. •Warning and Precautions:-
•Not for use in type 1 diabetes, diabetes ketoacidosis
•D/c if pancreatitis is suspected
•Use with caution in patients with abnormal LFTs
Patient counselling:-
•Avoid alcohol consumption
•If a dose is missed not to take a double dose
•Inform signs / symptoms of pancreatitis
•Instruct to inform physician if unusual symptom
develops or if a symptom persists/worsens.